ClinicalTrials.gg
Status unknownNCT02294448Updated Nov 19, 2014

PopPK Profile of Qishe Pill: Study Protocol for a Phase I Clinical Trial

A Phase 1 interventional study of Qishe Pill in Individuality and Narrative Medicine, sponsored by Shanghai University of Traditional Chinese Medicine. Status unknown at 1 site in China. Open to participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-19.

Sponsored by Shanghai University of Traditional Chinese Medicine · Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Nov 2014), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
All
01

Study summary

Qishe Pill (Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China), composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, has been developed and spread in use into clinical settings in 2009. As individualization has become the trend of modern medicine, a personalized medicine of Qishe Pill should be documented and practiced with various patients according to the ancient TCM system, a classification of personalized constitution type, which has been established to determine predisposition and prognosis to diseases as well as therapy and life-style administration. Therefore, we describe the population pharmacokinetic profile of Qishe Pill and compare its extent of metabolism in the 3 major Constitution Type (Qi-Deficiency, Yin-Deficiency and Blood-Stasis) to address major challenges of individualized and standardized Traditional Chinese Medicine into clinical practice.

Read the detailed description

With the greatly increased morbidity of neck pain, it brought a large challenge to some optimal therapies for various situations in population at a given time based on their demographic, physiological and pathological characteristics. Chinese proprietary herbal medicines, as a kind of Complementary and Alternative Medicine (CAM), are usually developed from some well-established and long-standing recipes and formulated as tablets or capsules for commerce, convenience or palatability. Although these advantage mentioned, a good quantification and a strict standardization in detail are still need to be improved for individualized implementation in therapeutic strategies. Based on the YQHY decoction (Yi-Qi Hua-Yu Decoction, tonify Qi and promoting circulation and removing stasis), Qishe Pill (Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China) has been developed and spread in use into clinical settings in 2009. As individualization has become the trend of modern medicine, a personalized medicine of Qishe Pill should be documented and practiced with various patients according to the ancient TCM system, a classification of personalized constitution type, which has been established to determine predisposition and prognosis to diseases as well as therapy and life-style administration. Therefore, we describe the population pharmacokinetic profile of Qishe Pill and compare its extent of metabolism in the 3 major Constitution Type (Qi-Deficiency, Yin-Deficiency and Blood-Stasis) to address major challenges of individualized and standardized Traditional Chinese Medicine into clinical practice.

02

Conditions studied

  • Individuality
  • Narrative Medicine

Keywords

  • Cervical radiculopathy
  • Neck pain
  • Qishe pill
  • raditional Chinese medicine
  • healthy Chinese subject
  • Population Pharmacokinetics
  • Personalized Medicine
  • Individualized Medicine
03

In context

Narrative Medicine

20 studies on the registry are indexed under Narrative Medicine; 8 are open to participants now.

This study's planned enrollment of 36 is below the median of 60 across 12 interventional studies indexed under Narrative Medicine.

Browse Narrative Medicine studies →

Lead sponsor

Shanghai University of Traditional Chinese Medicine is the lead sponsor of 102 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 20-35
  • 18.5 kg/m2 ≤ (BMI) \<23 kg/m2
  • TCM-constitutionally typed as either the 3 major type

Exclusion criteria

Exclusion

  • History of impaired fasting glucose or diabetes mellitus (past history of diabetes or fasting blood glucose at screening ≥100 mg/dl)
  • History of liver disease (hepatitis, hepatic cirrhosis) or hepatic dysfunction ( or ALT at screening ≥40 U/L)
  • History of renal dysfunction (creatinine at screening ≥1.2 mg/dl)
  • History of heart disease (heart failure, angina pectoris, myocardial infarction, arrhythmia)
  • History of malignant tumor
  • Having digestive disorders that can interfere with normal absorption of standard diet (gastritis, gastric ulcer, duodenitis, duodenal ulcer, etc.)
  • Smoking during the recent 3 months
  • Alcohol consumption 3 or more times a week during the recent 3 months
  • Women who were pregnant, intended to become pregnant, or breast- feeding
  • Medicated during the recent month for therapeutic or prophylactic purposes
  • Participating in another clinical trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    cohort 1

    Qishe Pill(Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China) in low dosage(3.75mg)

    Drug: Qishe Pill

  • Experimental
    cohort 2

    Qishe Pill(Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China) in medial dosage(7.5mg)

    Drug: Qishe Pill

  • Experimental
    cohort 3

    Qishe Pill(Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China)in high dosage(15mg)

    Drug: Qishe Pill

Interventions

  • DrugQishe Pill

    Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast

06

What researchers measure

Primary outcomes

  1. Plasma concentration of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: Dosing(0 hour)

  2. Plasma concentration of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 15 min after dosing

  3. Plasma concentration of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 30 min after dosing

  4. Plasma concentration of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 45 min after dosing

  5. Plasma concentration of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 60 min after dosing

  6. Plasma concentration of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 90 min after dosing

  7. Plasma concentration of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 120 min after dosing

  8. Plasma concentration of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 150 min after dosing

  9. Plasma concentration of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 180 min after dosing

  10. Plasma concentration of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 240 min after dosing

  11. Plasma concentration of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 360 min after dosing

  12. Plasma concentration of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 480 min after dosing

  13. Plasma concentration of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 600 min after dosing

  14. Plasma concentration of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 720 min after dosing

  15. Plasma concentrations of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 1440 min after dosing

  16. Plasma concentration of Qishe Pill

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 2160 min after dosing

  17. Plasma sampling of Qishe Pill for pharmacokinetic analysis

    5 ml blood samples for pharmacokinetic analysis

    Time frame: 2880 min after dosing

  18. Vital signs

    body temperature, heart rate and blood pressure

    Time frame: Dosing(0 hour)

  19. Vital signs

    body temperature, heart rate and blood pressure

    Time frame: 180 min after dosing

  20. Vital signs

    body temperature, heart rate and blood pressure

    Time frame: 720 min after dosing

  21. Vital signs

    body temperature, heart rate and blood pressure

    Time frame: 1440 min after dosing

  22. Vital signs

    body temperature, heart rate and blood pressure

    Time frame: 2160 min after dosing

  23. Vital signs

    body temperature, heart rate and blood pressure

    Time frame: 2880 min after dosing

  24. ECG monitoring

    Electrocardiograms (ECGs)

    Time frame: Dosing(0 hour)

  25. ECG monitoring

    Electrocardiograms (ECGs)

    Time frame: 180 min after dosing

  26. ECG monitoring

    Electrocardiograms (ECGs)

    Time frame: 720 min after dosing

  27. ECG monitoring

    Electrocardiograms (ECGs)

    Time frame: 1440 min after dosing

  28. ECG monitoring

    Electrocardiograms (ECGs)

    Time frame: 2160 min after dosing

  29. ECG monitoring

    Electrocardiograms (ECGs)

    Time frame: 2880 min after dosing

  30. Number of Participants with Adverse Events

    The investigators will assess all clinical AEs according to the Medical Dictionary for Regular Activities criteria, in terms of intensity (mild, moderate, or severe), duration, outcome and relationship to the study drug.

    Time frame: Day 1 of drug administration and blood sampling

  31. Number of Participants with Adverse Events

    The investigators will assess all clinical AEs according to the Medical Dictionary for Regular Activities criteria, in terms of intensity (mild, moderate, or severe), duration, outcome and relationship to the study drug.

    Time frame: Day 2 of drug administration and blood sampling

  32. Number of Participants with Adverse Events

    The investigators will assess all clinical AEs according to the Medical Dictionary for Regular Activities criteria, in terms of intensity (mild, moderate, or severe), duration, outcome and relationship to the study drug.

    Time frame: Day 3 of drug administration and blood sampling

  33. Number of Participants with Adverse Events

    Subjects will be requested to return to the study unit 4 d after drug administration and blood sampling for a follow-up visit.

    Time frame: 4 days after drug administration and blood sampling

  34. Peak Plasma Concentration (Cmax) of Qishe Pill in low dosage

    The maximum plasma concentration

    Time frame: 4 days after drug administration and blood sampling

  35. Peak Plasma Concentration (Cmax) of Qishe Pill in medial dosage

    The maximum plasma concentration

    Time frame: 4 days after drug administration and blood sampling

  36. Peak Plasma Concentration (Cmax) of Qishe Pill in high dosage

    The maximum plasma concentration

    Time frame: 4 days after drug administration and blood sampling

  37. The Time to Peak Plasma Concentration (Tmax) of Qishe Pill in low dosage

    The time to maximum concentration

    Time frame: 4 days after drug administration and blood sampling

  38. The Time to Peak Plasma Concentration (Tmax) of Qishe Pill in medial dosage

    The time to maximum concentration

    Time frame: 4 days after drug administration and blood sampling

  39. The Time to Peak Plasma Concentration (Tmax) of Qishe Pill in high dosage

    The time to maximum concentration

    Time frame: 4 days after drug administration and blood sampling

  40. Area under the Plasma Concentration versus Time Curve (AUC) of Qishe Pill in low dosage

    The area under the plasma concentration-time curve (AUC) will be calculated using the linear trapezoidal rule.

    Time frame: 4 days after drug administration and blood sampling

  41. Area under the Plasma Concentration versus Time Curve (AUC) of Qishe Pill in medial dosage

    The area under the plasma concentration-time curve (AUC) will be calculated using the linear trapezoidal rule.

    Time frame: 4 days after drug administration and blood sampling

  42. Area under the Plasma Concentration versus Time Curve (AUC) of Qishe Pill in high dosage

    The area under the plasma concentration-time curve (AUC) will be calculated using the linear trapezoidal rule.

    Time frame: 4 days after drug administration and blood sampling

  43. The distribution volume (DF) of Qishe Pill in low dosage

    The distribution volume (DF) will be calculated by Dose/AUC/ke. ke is the elimination rate constant.

    Time frame: 4 days after drug administration and blood sampling

  44. The distribution volume (DF) of Qishe Pill in medial dosage

    The distribution volume (DF) will be calculated by Dose/AUC/ke. ke is the elimination rate constant.

    Time frame: 4 days after drug administration and blood sampling

  45. The distribution volume (DF) of Qishe Pill in high dosage

    The distribution volume (DF) will be calculated by Dose/AUC/ke. ke is the elimination rate constant.

    Time frame: 4 days after drug administration and blood sampling

Secondary outcomes

  1. Deep phenotyping with genomics and functional genomics approaches

    3 ml blood samples for genomic variants analysis. The cytochrome P450 gene family, such as CYP1A1, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP3A4 and CYP3A5 , etc, will be chosen as the target objective.

    Time frame: Dosing(0 hour)

  2. Deep phenotyping with genomics and functional genomics approaches

    3 ml blood samples for genomic variants analysis. The cytochrome P450 gene family, such as CYP1A1, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP3A4 and CYP3A5 , etc, will be chosen as the target objective.

    Time frame: 2880 min after dosing

Other outcomes

  1. The Constitution in Chinese Medicine Questionnaire (CCMQ)

    Two qualified traditional Chinese medical doctors licensed by the Chinese government determine the constitution according to CCMQ

    Time frame: During screening in the recuitment

  2. The Constitution in Chinese Medicine Questionnaire (CCMQ)

    Two qualified traditional Chinese medical doctors licensed by the Chinese government determine the constitution according to CCMQ

    Time frame: 2880 min after dosing

  3. Laboratory measures and clinical assessment

    These parameters including blood count, electrolytes, renal and liver function parameters, blood lipids, age, gender, history of smoking, blood pressure, weight (kg), and height (meters) will be obtained for all subjects.

    Time frame: During screening in the recuitment

07

Study locations

1 of 1 sites recruiting
  • Longhua Hospital, Shanghai University of TCM
    Shanghai,, Shanghai 200032, China
    Recruiting
08

References and documents

Publications

  • Aker PD, Gross AR, Goldsmith CH, Peloso P. Conservative management of mechanical neck pain: systematic overview and meta-analysis. BMJ. 1996 Nov 23;313(7068):1291-6. PubMed 8942688 ↗
  • Cui X, Trinh K, Wang YJ. Chinese herbal medicine for chronic neck pain due to cervical degenerative disc disease. Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD006556. doi: 10.1002/14651858.CD006556.pub2. PubMed 20091597 ↗
  • Wang Q. Classification of the nine basic TCM constitutional type and based expression and diagnosis. Journal of Beijing University of Traditional Chinese medicine. 2005.1-8
  • Liu Mei, Zhang N, Wang YJ, Shi Q. Purification process research of major compound in Qishe Pill as Astragalus. Acta Chinese Medicine and Pharmacology. 2006(34):14-16.
  • Zhang YQ, Liu XH, Zhang N, Liu M. Quality standard research of Qishe Pill. Lishizhen Med Mater Med Res. 2008(19): 977-979.
  • Liu M, Zhang N, Wang YJ, Zhang YQ, Zhou CJ. Technology research of Qishe Pill, a new medicine for cervical spondylosis. Lishizhen Med Mater Med Res. 2010(21):176-179.
  • Ge JR, Wang HM, Meng CX, Tong PJ. Effects of Qishe Pill, a compound traditional Chinese herbal medicine, on cervical radiculopathy: a randomized controlled trial for Phase III. Chinese Journal of New Drugs and Clinical. 2014(7):56-58.
  • Johnson CL, Fulwood R, Abraham S, Bryner JD. Basic data on anthropometric measurements and angular measurements of the hip and knee joints for selected age groups 1-74 years of age. Vital Health Stat 11. 1981 Apr;(219):1-68. No abstract available. PubMed 15806754 ↗
  • Makela M, Heliovaara M, Sievers K, Impivaara O, Knekt P, Aromaa A. Prevalence, determinants, and consequences of chronic neck pain in Finland. Am J Epidemiol. 1991 Dec 1;134(11):1356-67. doi: 10.1093/oxfordjournals.aje.a116038. PubMed 1755449 ↗
  • Bovim G, Schrader H, Sand T. Neck pain in the general population. Spine (Phila Pa 1976). 1994 Jun 15;19(12):1307-9. doi: 10.1097/00007632-199406000-00001. PubMed 8066508 ↗
  • van der Donk J, Schouten JS, Passchier J, van Romunde LK, Valkenburg HA. The associations of neck pain with radiological abnormalities of the cervical spine and personality traits in a general population. J Rheumatol. 1991 Dec;18(12):1884-9. PubMed 1795327 ↗
  • Hsu H-Y: 1986 Oriental MateriaMedica. Long Beach, CA: Oriental Healing Arts Institute; 1986.
  • Zhu YB, Wang Q, Xue HS, Origasa H. Preliminary assessment on performance of constitution in Chinese medicine questionnaire. ZhongGuo Lin Chuang Kang Fu 2006; 10 (3): 15-17.
  • FDA/CDER. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers; 2005, http://www.fda.gov/downloads/drugs/guidance-complianceregulatoryinformation/guidances/ucm078932.pdf.
  • van Gerven J, Bonelli M. Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. Br J Clin Pharmacol. 2018 Jul;84(7):1401-1409. doi: 10.1111/bcp.13550. Epub 2018 May 30. No abstract available. PubMed 29451320 ↗
  • Choo V. WHO reassesses appropriate body-mass index for Asian populations. Lancet. 2002 Jul 20;360(9328):235. doi: 10.1016/S0140-6736(02)09512-0. No abstract available. PubMed 12133671 ↗
  • Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980 Dec;8(6):553-71. doi: 10.1007/BF01060053. PubMed 7229908 ↗
  • Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm. 1981 Oct;9(5):635-51. doi: 10.1007/BF01061030. PubMed 7334463 ↗
  • Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1983 Jun;11(3):303-19. doi: 10.1007/BF01061870. PubMed 6644555 ↗
  • Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, Aravagiri M, Schneider L, Bies RR. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol. 2008 Nov;66(5):629-39. doi: 10.1111/j.1365-2125.2008.03276.x. Epub 2008 Jul 31. PubMed 18771484 ↗
  • Zhang WJ, Hufnagl P, Binder BR, Wojta J. Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF-kappaB activation and adhesion molecule expression. Thromb Haemost. 2003 Nov;90(5):904-14. doi: 10.1160/TH03-03-0136. PubMed 14597987 ↗
  • Sun YL, Hou T, Liu SF, Zhang ZL, Zhang N, Yao M, Yang L, Shi Q, Cui XJ, Wang YJ. Population pharmacokinetic modeling of the Qishe pill in three major traditional Chinese medicine-defined constitutional types of healthy Chinese subjects: study protocol for a randomized controlled trial. Trials. 2015 Feb 26;16:64. doi: 10.1186/s13063-015-0568-6. PubMed 25885543 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Dec 2015 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2014
First posted
Nov 19, 2014
Start
Nov 2014
Primary completionEst.
Dec 2015
CompletionEst.
Jul 2016
Last update
Nov 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02294448
Responsible party
Cui xuejun (Vice director, Shanghai University of Traditional Chinese Medicine) — Principal investigator
First posted
Nov 19, 2014
Start date
Nov 2014
Primary completion
Dec 2015 (estimated)
Completion
Jul 2016 (estimated)
Last update
Nov 19, 2014

Study contacts

Xue-Jun Cui, Dr.
Contact
13917715524@139.com
Yue-li Sun, Dr
Contact
edisonlike2008@gmail.com
Yong-jun Wang, Dr.
principal investigator · Longhua Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion